Infections in the Immunocompromised Host — Written Clinical Reasoning

SAQ 1 — Integrated Management of Febrile Neutropenia (20 marks, 30 minutes)

Prompt: Outline your integrated management plan for this patient with febrile neutropenia, including: (a) the definition you are applying and the immediate empiric antibiotic regimen with exact drug, dose, route, and timing, and why; (b) your decision regarding additional Gram-positive cover in this specific patient; (c) the escalation strategy if fever persists at day 3 to 5; (d) the role of granulocyte colony-stimulating factor in this episode and why; (e) the principles guiding antibiotic duration and cessation; and (f) the high-yield exam traps in febrile neutropenia management. [1]

Model Answer

(a) Definition and immediate empiric regimen (4 marks): [1]

This patient meets the definition of febrile neutropenia: a single temperature above 38.3 degrees Celsius in a patient with an absolute neutrophil count below 0.5 x 10^9 per litre (he is profoundly neutropenic at 0.1) [1]. The IDSA 2011 guideline mandates empiric broad-spectrum antipseudomonal antibiotic therapy within one hour of the fever reading, and the blood cultures I have drawn do not delay the first dose. The empiric regimen is piperacillin-tazobactam 4.5 g intravenously every 6 to 8 hours (the ANZ first-line agent), which provides cover against Pseudomonas aeruginosa (the organism with the highest untreated mortality in neutropenia and the one the empiric regimen MUST cover from the first dose), other Gram-negative bacilli, anaerobes, and many Gram-positive organisms. The rationale for monotherapy over beta-lactam-aminoglycoside combination is that a Cochrane review of 71 trials found beta-lactam monotherapy to be as effective as combination, with significantly less nephrotoxicity [2]. I would not delay the first dose for the blood culture results, the white cell count trend, or any investigation — the door-to-antibiotic time is a key determinant of mortality.

(b) Additional Gram-positive cover — the decision in this patient (3 marks): [1]

I would add vancomycin to the empiric regimen in this specific patient, for two of the guideline indications [1]: severe mucositis on fluoroquinolone prophylaxis (viridans streptococci are the concern — they colonise damaged oral mucosa and cause rapidly progressive bacteraemia, and ciprofloxacin prophylaxis selects for resistant strains), and possible line-related infection (exit-site erythema, even without purulence or tenderness, raises the possibility of catheter-related bloodstream infection with coagulase-negative staphylococci or Staphylococcus aureus). I would NOT add vancomycin routinely to every febrile neutropenic patient — the guideline explicitly limits its use to specific indications (line infection, severe sepsis or shock, pneumonia, skin or soft-tissue infection, MRSA colonisation, severe mucositis on fluoroquinolone prophylaxis, or a positive Gram-positive blood culture), because routine vancomycin increases nephrotoxicity without improving outcomes. The vancomycin dose is weight-based (typically 15 to 20 mg/kg every 8 to 12 hours, with trough or AUC monitoring). I would review the line — uncomplicated exit-site infection can be managed with the line in situ and antibiotics, but tunnel infection, port abscess, septic emboli, or endocarditis mandate removal, as does persistent Staphylococcus aureus, Pseudomonas, or Candida bacteraemia.

(c) Escalation if fever persists at day 3 to 5 (4 marks): [1]

Persistent fever beyond 3 to 5 days despite broad-spectrum antibacterials raises the concern of invasive fungal infection (Aspergillus, Candida, Mucorales) or an undrained focus. The escalation steps are: (1) review the clinical picture and cultures — is there a new focus (pulmonary, sinus, abdominal, perianal)?; (2) order a high-resolution chest CT (the chest X-ray is often normal early — the CT is the test that finds the halo sign of invasive aspergillosis, the reverse halo of Mucorales, and nodules); (3) send a serum galactomannan (Aspergillus cell-wall antigen; serial monitoring improves sensitivity) and consider a beta-D-glucan; (4) consider bronchoalveolar lavage if there are pulmonary findings, for galactomannan, culture, and molecular testing; (5) add empiric antifungal therapy — liposomal amphotericin B 3 mg/kg daily, an echinocandin (caspofungin 70 mg loading then 50 mg daily, or micafungin), or voriconazole or posaconazole. The choice is guided by the clinical syndrome (liposomal amphotericin B for broad mould cover including Mucorales; voriconazole or isavuconazole if invasive aspergillosis is confirmed; an echinocandin for candidemia). If a focus is identified (for example, a perianal abscess, typhlitis, sinusitis), it must be drained or debrided where possible. [1]

(d) The role of G-CSF (3 marks): [1]

I would not give G-CSF routinely for this episode of established febrile neutropenia. A Cochrane review of 14 randomised controlled trials (1,553 participants) found that adding colony-stimulating factors to antibiotics did not significantly reduce overall mortality (hazard ratio 0.74, 95 per cent CI 0.47 to 1.16) [3]. Although G-CSF modestly shortens the duration of neutropenia, this does not translate into a survival benefit. I would reserve G-CSF for selected patients with features predicting a poor outcome — profound and prolonged neutropenia expected to last beyond 10 days, pneumonia, invasive fungal infection, hypotension or multi-organ dysfunction, or age over 65 — as a considered decision rather than a reflex. Its legitimate role is primary prophylaxis (given after chemotherapy to patients whose regimen carries an expected febrile neutropenia risk above 20 per cent) and secondary prophylaxis (after a confirmed episode, to allow maintenance of dose intensity). The common error is giving G-CSF reflexively for every febrile neutropenic patient — it does not save lives and it does not substitute for antibiotics.

(e) Duration and cessation (3 marks): [1]

I would continue the empiric antibiotics until the patient has been afebrile for at least 48 hours AND the neutrophil count is recovering (above 0.5 x 10^9 per litre and rising) [1]. If a pathogen is identified, I narrow to targeted therapy and treat for the standard course for that organism and focus. If cultures remain negative and the patient recovers, I continue the empiric regimen until the neutrophils recover. If the patient has prolonged neutropenia and a documented infection (for example, a bacteraemia), I treat for the standard course for that organism regardless of the neutrophil count. I would not stop antibiotics simply because the fever has settled if the neutrophils have not recovered — the risk of relapse and of selection of resistant organisms is real. If the patient is clinically well, cultures are negative, and the MASCC score identifies low risk (at least 21), I consider step-down to oral ciprofloxacin plus amoxicillin-clavulanate and, in selected cases, outpatient management with close follow-up.

(f) High-yield exam traps (3 marks): [1]

The traps are: (1) delaying antibiotics for cultures or a rising count — the door-to-antibiotic time must be within one hour; (2) adding vancomycin routinely to every regimen — it increases nephrotoxicity without benefit and is reserved for specific indications; (3) giving G-CSF routinely for established febrile neutropenia — no mortality benefit; its role is prophylaxis; (4) accepting a normal chest X-ray as exclusion of invasive aspergillosis — the chest CT is the test that finds the halo sign; (5) stopping antibiotics before neutrophil recovery because the fever has settled — continue until afebrile for 48 hours AND neutrophils recovering; (6) missing a perianal source — examine the perianal area in every febrile neutropenic patient, because perianal cellulitis or a fissure can be the source and may need specific management including avoidance of digital rectal examination. [1]

SAQ 2 — Prevention of Hepatitis B Reactivation Before Rituximab (10 marks)

Prompt: A 58-year-old woman with newly diagnosed diffuse large B-cell lymphoma is about to start R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone). Her pre-treatment viral screen shows HBsAg negative, anti-HBc (total) positive, anti-HBs positive, HBV DNA undetectable, and ALT normal. She is originally from Vietnam. Outline: (a) what this serology means and the risk she faces; (b) the pathophysiology of rituximab-associated HBV reactivation; (c) the recommended prophylaxis with exact agent, dose, and duration; (d) the screening principle that should apply to every patient before rituximab or chemotherapy; and (e) why a "treat-on-flare" strategy is inferior to prophylaxis in this patient. [1]

Model Answer

(a) What the serology means and the risk (2 marks): [1]

This patient has resolved hepatitis B — she is HBsAg-negative (no active infection), anti-HBc-positive (past exposure), and anti-HBs-positive (recovered, with antibody). The risk she faces is HBV reactivation under rituximab: even from this resolved state, the virus — which persists in the liver as covalently closed circular DNA — can reactivate when the immune control that holds it in check is removed. Reactivation presents as rising HBV DNA and ALT 2 to 12 months after rituximab, sometimes as fulminant hepatic failure with significant mortality. The risk is highest in patients who are HBsAg-positive (reactivation rate up to 50 per cent without prophylaxis) but is real and documented in anti-HBc-positive/HBsAg-negative patients on rituximab (reactivation rate 10 to 20 per cent). Her Vietnamese origin puts her in a high-prevalence population where past HBV exposure is common. [1]

(b) Pathophysiology (2 marks): [1]

Rituximab is a chimeric monoclonal antibody against CD20 on B-cells, and it depletes B-cells for 6 to 12 months. The B-cell response — and specifically the production of anti-HBs antibody — is the immune mechanism that holds HBV in check in a resolved infection. When rituximab removes those antibody-producing cells, the residual HBV in the liver is no longer neutralised, viral replication resumes, and infected hepatocytes are subsequently destroyed when immune recovery occurs (or the virus causes direct cytopathic injury). The window of vulnerability extends well beyond the lymphoma treatment course, because B-cell depletion persists for months after the last rituximab dose. [1]

(c) Recommended prophylaxis (2 marks): [1]

I would commence entecavir 0.5 mg orally daily (or tenofovir disoproxil fumarate 300 mg daily) before the first rituximab dose, continue it through the treatment course, and for at least 12 to 18 months after the last rituximab dose, with monitoring of ALT and HBV DNA every 3 months during therapy and for at least 12 months after cessation. Entecavir and tenofovir are both preferred over lamivudine, because lamivudine has a high rate of resistance with prolonged use. A systematic review confirmed that preventive antiviral therapy dramatically reduces HBV reactivation and HBV-related hepatic failure [4]. Renal dose adjustment is required for both entecavir and tenofovir.

(d) The screening principle (2 marks): [1]

Every patient about to receive rituximab, chemotherapy, or any B-cell-depleting therapy must be screened for HBV with HBsAg, anti-HBc, and anti-HBs (and HBV DNA if any are positive) — not just HBsAg. Screening only for HBsAg misses the anti-HBc-positive/HBsAg-negative resolved-infection patient, who is exactly the patient in whom reactivation is most often overlooked and most dangerous. This is one of the clearest wins in preventive medicine — a single blood test identifies every at-risk patient, and a single daily tablet prevents a potentially fatal complication. [1]

(e) Why treat-on-flare is inferior (2 marks): [1]

A pre-emptive (treat-on-flare) strategy — monitoring ALT and HBV DNA and starting the antiviral only when viraemia rises — is inferior to universal prophylaxis in patients receiving rituximab, for three reasons. First, by the time HBV DNA rises and ALT follows, viral replication is already established and the risk of fulminant failure is real. Second, the monitoring burden is high and adherence is imperfect in an outpatient lymphoma population. Third, reactivation under rituximab is particularly aggressive because B-cell recovery lags well beyond the treatment course, so the window of vulnerability is long. The published evidence and the hepatology and oncology guideline consensus is that resolved HBV plus rituximab equals prophylaxis, not surveillance. The trap is treating this resolved-infection patient as "low risk" and offering surveillance — she is not low risk under rituximab, and prophylaxis is the standard of care. [1]